Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.

The FEV(1) declines rapidly in alpha(1)-antitrypsin deficiency (alpha(1)-ATD) but less is known about other measures of disease severity and the factors, other than smoking, that are associated with progression of emphysema. The natural history of alpha(1)-ATD was studied prospectively in 43 patients with the PiZ phenotype and emphysema at a single center over 2 yr. The mean +/- SE change in FEV(1) was -67 +/- 14 ml/yr, accompanied by a reduction in transfer factor (mean change in diffusing capacity of the lung for CO [DL(CO)] -1.07 +/- 0.21 ml/min/mm Hg/yr; p < 0.001) and lung density in the upper zones as assessed by quantitative high-resolution computed tomography (HRCT) (mean change in voxel index 2.8 +/- 0.6%/yr; p < 0.001). The decline in FEV(1) related to baseline FEV(1) (r = -0.56, p < 0.001), bronchodilator reversibility (r = 0.52, p < 0.001), and (for patients with FEV(1) > 35% predicted) exacerbation frequency (r = -0.38, p = 0.02). There was also a decline in the St. George's Respiratory Questionnaire (SGRQ) Activity score (mean change -4.3 +/- 1.2 units/yr, p < 0.001) that correlated with FEV(1) decline (r = 0.45, p = 0.002). Progression of emphysema in alpha(1)-ATD is dependent on baseline physiology and exacerbation frequency and may be detected by several different measurements of which HRCT density mask analysis and DL(CO) appear most sensitive.

[1]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[2]  R. Stockley,et al.  High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. , 2001, The European respiratory journal.

[3]  N. Konietzko,et al.  Longitudinal Follow-up of Patients With α1-Protease Inhibitor Deficiency Before and During Therapy With IV α1-Protease Inhibitor , 2001 .

[4]  R. Stockley,et al.  Exercise capacity predicts health status in α1-Antitrypsin deficiency , 2001 .

[5]  J. Lieberman.  Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. , 2000, Chest.

[6]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[7]  R. Stockley,et al.  Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). , 1999, American journal of respiratory and critical care medicine.

[8]  H A Vrooman,et al.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.

[9]  Lene Theil Skovgaard,et al.  Progress of emphysema in severe α1-Antitrypsin Deficiency as Assessed by Annual CT , 1997 .

[10]  P. Gevenois,et al.  The effects of age, sex, lung size, and hyperinflation on CT lung densitometry. , 1996, AJR. American journal of roentgenology.

[11]  J. Connett,et al.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.

[12]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[13]  C. Roberts,et al.  Arterialised earlobe blood gas analysis: an underused technique. , 1994, Thorax.

[14]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[15]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[16]  D. Naidich.  High-resolution computed tomography of cystic lung disease. , 1991, Seminars in roentgenology.

[17]  N. Müller,et al.  "Density mask". An objective method to quantitate emphysema using computed tomography. , 1988, Chest.

[18]  A. E. Anderson,et al.  Small airways in severe panlobular emphysema: mural thickening and premature closure. , 2015, The American review of respiratory disease.

[19]  B. Burrows.  A clinical trial of efficacy of antiproteolytic therapy: can it be done? , 2015, The American review of respiratory disease.